Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 studyJianming Xu, Weiguo Su, Zhiping Li et al.|The Lancet Oncology|2020Cited by 193
Efficacy and safety of surufatinib in patients with well-differentiated advanced extrapancreatic neuroendocrine tumors (NETs): Results from the randomized phase III study (SANET-ep)Jihong Xu, W. Su, Lin Shen et al.|Annals of Oncology|2019Cited by 17
Health-related quality-of-life results from SANET-ep: A phase III study of surufatinib versus placebo for advanced extrapancreatic neuroendocrine tumors.Chunmei Bai, Weiguo Su, Jianming Xu et al.|Journal of Clinical Oncology|2020Cited by 1